SPY332.11+2.05 0.62%
DIA272.00+3.59 1.34%
IXIC10,998.40+57.23 0.52%

Corvus Pharmaceuticals Q2 EPS $(0.36) Misses $(0.28) Estimate

Corvus Pharmaceuticals (NASDAQ:CRVS) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 18.18 percent increase over losses of $(0.44) per

Benzinga · -
Corvus Pharmaceuticals (NASDAQ: CRVS) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 18.18 percent increase over losses of $(0.44) per share from the same period last year.